We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Avadel Pharmaceuticals plc (AVDL) USD0.01

Sell:$10.00 Buy:$10.78 Change: $0.20 (1.98%)
Market closed |  Prices as at close on 20 December 2024 | Switch to live prices |
Sell:$10.00
Buy:$10.78
Change: $0.20 (1.98%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 20 December 2024 | Switch to live prices |
Sell:$10.00
Buy:$10.78
Change: $0.20 (1.98%)
Market closed |  Prices as at close on 20 December 2024 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Avadel Pharmaceuticals PLC is a biopharmaceutical company. The Company's product, LUMRYZ, is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. Its approach includes applying solutions to the development of medications that address the patients face with treatment options. Its drug delivery technologies include MICROPUMP, LIQUITIME and MEDUSA. Its MICROPUMP technology allows for the development of modified release solid, oral dosage formulations of drugs. Its LIQUITIME technology allows for the development of modified release oral products in a liquid suspension formulation, which may make such formulations particularly suited for children and/or patients having issues swallowing tablets or capsules. Its MEDUSA technology allows for the development of modified-release injectable dosage formulations of drugs.

Contact details

Address:
Block 10-1 Blanchardstown Corporate Park
Ballycoolin
DUBLIN
15
Ireland
Telephone:
+353 (1) 9015201
Website:
https://www.avadel.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
AVDL
ISIN:
IE00BDGMC594
Market cap:
$995.41 million
Shares in issue:
96.36 million
Sector:
Pharmaceuticals
Exchange:
NASDAQ
Country:
Ireland
Currency:
US dollar
Indices:
n/a

Key personnel

  • Gregory Divis
    Chief Executive Officer, Director
  • Thomas Mchugh
    Chief Financial Officer
  • Jerad Seurer
    General Counsel and Corporate Secretary
  • Richard Kim
    Chief Commercial Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.